Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes

Launched by UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST · Oct 15, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how different health services and support affect the quality of life for patients with certain types of atypical Parkinsonian syndromes, specifically progressive supranuclear palsy, corticobasal degeneration, and multiple system atrophy. The researchers want to see if having access to specialized clinics makes a difference in patients' health and well-being compared to those receiving care in areas without these clinics. By understanding the best services for these patients and their caregivers, the study aims to improve care and support for everyone affected by these conditions.

To participate in this trial, individuals must be 18 years or older and have a diagnosed neurodegenerative disease, including the specific types mentioned above. Patients and their caregivers will need to be able to provide consent to take part in the study. Throughout the trial, participants can expect to share their experiences with health services and how they feel about their quality of life, which will help researchers gather important information to enhance future care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients and their carers must:
• • Be aged 18 or over
• • Have capacity to consent at the beginning of their involvement
• • Have a diagnosis of a neurodegenerative disease which includes progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy but may include other closely related diseases where the presentation is similar, such as Alzheimer's disease where they present with a corticobasal syndrome
• Exclusion Criteria:
• • Patients or carers not meeting the inclusion criteria
• • Patients with static deficits only who do not have a neurodegenerative syndrome.
• • Patients who the principal investigator feels are not suitable to take part due to co-morbidities or participation in other trials.